Interleukin-13 / IL13 antibody

Principal name

Interleukin-13 / IL13 antibody

Alternative names for Interleukin-13 / IL13 antibody

IL-13, NC30

SwissProt ID

P20109 (Mouse), P35225 (Human), P42203 (Rat), Q95J68 (Pig), Q9N0W9 (Canfa), Q9XSV9 (Bovin)

Gene ID

3596 (IL13), 16163 (Il13), 116553, 396721

Available reactivities

Hu (Human), Ms (Mouse), Por (Porcine), Rt (Rat)

Available hosts

Rabbit, Mouse, Rat, Sheep

Available applications

Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Functional assay (FN), Paraffin Sections (P), Flow Cytometry (F), Immunocytochemistry/Immunofluorescence (ICC/IF), ELISA (capture) (E(capture)), ELISA (detection) (E(detection))

Background of Interleukin-13 / IL13 antibody

Interleukin-13 (IL-13) is a 17 kDa immunoregulatory cytokine that plays a key role in the pathogenesis of allergy, cancer, and tissue fibrosis . It is secreted by Th1, Th2, Th17, NK, and mast cells, visceral smooth muscle cells, eosinophils, and basophils . This pattern is similar to the expression of Interleukin-4 (IL-4) but also includes subsets of Th1 and Th17 cells that do not secrete IL-4 . IL-13 circulates as a monomer and has two internal disulfide bonds that contribute to its bundled four .-helix configuration . Mature human IL-13 shares approximately 58% amino acid sequence identity with mouse and rat IL-13. Despite the low homology, it exhibits cross-species activity between human, mouse, and rat . IL-13 suppresses the production of proinflammatory cytokines and other cytotoxic substances by macrophages, fibroblasts, and endothelial cells. On B cells, it promotes cellular activation, immunoglobulin class switching to IgE, and the upregulation of CD23/Fc. RII. Polymorphisms and upregulation of IL-13 are associated with atopy, asthma, airway hyperresponsiveness, and tissue fibrosis .

The biological effects of IL-13 and IL-4 are closely related due in part to a shared receptor system. IL-13 binds with low affinity to the transmembrane IL-13 R.1 which then forms a signaling complex with the transmembrane IL-4 R. . This high affinity receptor complex also functions as the type 2 IL-4 receptor . Soluble forms of IL-4 R. are expressed which retain ligand binding properties and inhibit IL-4 bioactivity . IL-4 R. also associates with the common gamma chain (.c) to form the type 1 IL-4 receptor complex .

Additionally, IL-13 binds with high affinity to IL-13 R.2 which is expressed as cell surface and soluble forms . IL-13 R.2 functions as a decoy receptor by preventing IL-13 from signaling through the IL-13 R.1/IL-4 R. complex . It also inhibits responsiveness to IL-4 by blocking signaling through IL-4-occupied IL-13 R.1/IL-4 R. receptor complexes . IL-13 R.2 is upregulated during Th2-biased immune responses and limits inflammatory tissue damage . Aside from its decoy function, IL-13 R.2 can signal in response to IL-13 to directly promote tumor cell invasiveness and the development of tissue fibrosis .

General readings

Townley, R.G. et al. (2011) Discov. Med. 12:513.

Wynn, T.A. (2003) Annu. Rev. Immunol. 21:425.

Joshi, B.H. et al. (2006) Vitam. Horm. 74:479.

McKenzie, A.N. et al. (1993) Proc. Natl. Acad. Sci. USA 90:3735.

Gallo, E. et al. (2012) Eur. J. Immunol. 42:2322.

Moy, F.J. et al. (2001) J. Mol. Biol. 310:219.

Eisenmesser, E.Z. et al. (2001) J. Mol. Biol. 310:231.

Ruetten, H. and C. Thiemermann (1997) Shock 8:409.

Lakkis, F.G. et al. (1997) Biochem. Biophys. Res. Commun. 235:529.

Liu, Y. et al. (2012) Front. Immunol. 3:1.

Aman, M.J. et al. (1996) J. Biol. Chem. 271:29265.

Zurawski, S.M. et al. (1995) J. Biol. Chem. 270:13869.

Andrews, A.L. et al. (2002) J. Biol. Chem. 277:46073.

Kruse, S. et al. (1999) Int. Immunol. 11:1965.

Jung, T. et al. (1999) Int. Arch. Allergy Immunol. 119:23.

Kondo, M. et al. (1993) Science 262:1874.

Russell, S.M. et al. (1993) Science 262:1880.

Chen, W. et al. (2008) J. Allergy Clin. Immunol. 122:625.

Chen, W. et al. (2009) J. Immunol. 183:7870.

Daines, M.O. et al. (2007) J. Allergy Clin. Immunol. 119:375.

Kasaian, M.T. et al. (2011) J. Immunol. 187:561.

Andrews, A.-L. et al. (2006) J. Allergy Clin. Immunol. 118:858.

Rahaman, S.O. et al. (2002) Cancer Res. 62:1103.

Sivaprasad, U. et al. (2010) J. Immunol. 185:6802.

Chiaramonte, M.G. et al. (2003) J. Exp. Med. 197:687.

Fujisawa, T. et al. (2009) Cancer Res. 69:8678.

Fujisawa, T. et al. (2011) Int. J. Cancer 131:344.

Fichtner-Feigl, S. et al. (2006) Nat. Med. 12:99.

1 Item(s)

per page


Catalog No.    

IL13 overexpression lysate

IL13 overexpression lysate  
0.1 mg / €280.00
  OriGene Technologies, Inc.

1 Item(s)

per page
  • LinkedIn